AMGN, PFE And GILD, Pushing Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 60 points (0.4%) at 16,603 as of Friday, May 23, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,002 issues advancing vs. 938 declining with 179 unchanged.

The Drugs industry currently sits up 0.7% versus the S&P 500, which is up 0.3%. Top gainers within the industry include Isis Pharmaceuticals ( ISIS), up 9.4%, Alnylam Pharmaceuticals ( ALNY), up 6.2%, Valeant Pharmaceuticals International ( VRX), up 1.5%, Allergan ( AGN), up 1.3% and Alexion Pharmaceuticals ( ALXN), up 1.0%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Amgen ( AMGN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Amgen is down $0.60 (-0.5%) to $114.26 on light volume. Thus far, 1.4 million shares of Amgen exchanged hands as compared to its average daily volume of 3.9 million shares. The stock has ranged in price between $113.56-$115.12 after having opened the day at $114.99 as compared to the previous trading day's close of $114.86.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Amgen has a market cap of $85.9 billion and is part of the health care sector. Shares are up 0.7% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts that rate Amgen a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Pfizer ( PFE) is down $0.20 (-0.7%) to $29.46 on light volume. Thus far, 9.4 million shares of Pfizer exchanged hands as compared to its average daily volume of 31.1 million shares. The stock has ranged in price between $29.46-$29.64 after having opened the day at $29.57 as compared to the previous trading day's close of $29.66.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. Pfizer has a market cap of $188.6 billion and is part of the health care sector. Shares are down 3.2% year-to-date as of the close of trading on Thursday. Currently there are 6 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is down $1.44 (-1.7%) to $81.46 on average volume. Thus far, 7.2 million shares of Gilead exchanged hands as compared to its average daily volume of 16.9 million shares. The stock has ranged in price between $81.22-$82.50 after having opened the day at $82.43 as compared to the previous trading day's close of $82.90.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $125.6 billion and is part of the health care sector. Shares are up 10.4% year-to-date as of the close of trading on Thursday. Currently there are 17 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Gilead Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids

McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2